Searched for: author%3A%22Gusarova%2C+V.%22
(1 - 3 of 3)
List view
Grid view
document
Pouwer, M.G. (author), Pieterman, E.J. (author), Worms, N. (author), Keijzer, N. (author), Jukema, J.W. (author), Gromada, J. (author), Gusarova, V. (author), Princen, H.M.G. (author)
Atherosclerosis-related cardiovascular disease causes nearly 20 million deaths annually. Most patients are treated after plaques develop, so therapies must regress existing lesions. Current therapies reduce plaque volume, but targeting all apoB-containing lipoproteins with intensive combinations that include alirocumab or evinacumab-monoclonal...
article 2020
document
Dewey, F.E. (author), Gusarova, V. (author), Dunbar, R.L. (author), O'Dushlaine, C. (author), Schurmann, C. (author), Gottesman, O. (author), McCarthy, S. (author), van Hout, C.V. (author), Bruse, S. (author), Dansky, H.M. (author), Leader, J.B. (author), Murray, M.F. (author), Ritchie, M.D. (author), Kirchner, H.L. (author), Habegger, L. (author), Lopez, A. (author), Penn, J. (author), Zhao, A. (author), Shao, W. (author), Stahl, N. (author), Murphy, A.J. (author), Hamon, S. (author), Bouzelmat, A. (author), Zhang, R. (author), Shumel, B. (author), Pordy, R. (author), Gipe, D. (author), Herman, G.A. (author), Sheu, W.H.H. (author), Lee, I.T. (author), Liang, K.W. (author), Guo, X. (author), Rotter, J.I. (author), Chen, Y.I. (author), Kraus, W.E. (author), Shah, S.H. (author), Damrauer, S. (author), Small, A. (author), Rader, D.J. (author), Wulff, A.B. (author), Nordestgaard, B.G. (author), Tybjærg-Hansen, A. (author), van den Hoek, A.M. (author), Princen, H.M.G. (author), Ledbetter, D.H. (author), Carey, D.J. (author), Overton, J.D. (author), Reid, J.G. (author), Sasiela, W.J. (author), Banerjee, P. (author), Shuldiner, A.R. (author), Borecki, I.B. (author), Teslovich, T.M. (author), Yancopoulos, G.D. (author), Mellis, S.J. (author), Gromada, J. (author), Baras, A. (author)
Background Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. It is not known whether such variants or therapeutic antagonism of ANGPTL3 are associated with a reduced risk...
article 2017
document
Kühnast, S. (author), van der Hoorn, J.W.A. (author), Pieterman, E.J. (author), van den Hoek, A.M. (author), Sasiela, W.J. (author), Gusarova, V. (author), Peyman, A. (author), Schäfer, H.L. (author), Schwahn, U. (author), Jukema, J.W. (author), Princen, H.M.G. (author)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of alirocumab in APOE∗3Leiden. CETP mice. Mice received a Western-type diet and were treated with...
article 2014